DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Information source: GlaxoSmithKline
ClinicalTrials.gov processed this data on August 23, 2015
Link to the current ClinicalTrials.gov record.

Condition(s) targeted: Asthma

Intervention: Fluticasone propionate/salmeterol combination ED MD (Drug); Fluticasone propionate/salmeterol combination OP MD (Drug)

Phase: N/A

Status: Completed

Sponsored by: GlaxoSmithKline

Official(s) and/or principal investigator(s):
GSK Clinical Trials, Study Director, Affiliation: GlaxoSmithKline

Summary

The objective of this study is to compare readmission to the emergency department for asthma in asthma patients who receive treatment with fluticasone propionate and salmeterol oral inhaler after an initial emergency department visit using a retrospective observational cohort study design.

Clinical Details

Official title: Use of Fluticasone Propionate/Salmeterol Combination Post Emergency Department Visit

Study design: Observational Model: Cohort, Time Perspective: Retrospective

Primary outcome: Number of Participants With an Asthma-related Event Occurring Between 1 and 6 Months Following the Index Event

Eligibility

Minimum age: 12 Years. Maximum age: N/A. Gender(s): Both.

Criteria:

Inclusion Criteria:

- Subjects with asthma as determined by ICD-9 codes and asthma drug use

- at least 12 years of age

- discharged from an initial Emergency Department visit within 12 months

Exclusion Criteria:

- Subjects with COPD or treatment for COPD

Locations and Contacts

Additional Information

Starting date: June 2009
Last updated: October 20, 2011

Page last updated: August 23, 2015

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017